主要科研方向：（1）艰难梭菌、脆弱拟杆菌等厌氧菌感染发病机制、耐药机制以及新药研发；（2）抗感染新药临床转化研究。作为项目负责人完成国家自然科学基金 3 项、科技部重大新药创制子课题一项以及省部级课题5项，在研上海市科委课题1项。作为Leading PI牵头抗感染新药多中心临床注册试验21项。迄今以一作/通讯（含共同）SCI文章40 篇，其中包括Clin Infect Dis, Clin Microbio Infect, Int J Antimicrob Agents等。2012年获浦江人才项目支持。 重要论文： (1) Teng Xu; Ying Zhou; Qingqing Xu; Li Wang; Yu Zhou; Shi Wu; Haihui Huang; ATP-binding cassette transporters mediate and regulate metronidazole resistance in Clostridioides difficile,International Journal of Antimicrobial Agents, 2026, 67(2) . (2) Li Wang; Teng Xu; Shi Wu; Chao Zhao; Haihui Huang; The efficacy and underlying mechanismsof berberine in the treatment of recurrent Clostridioides difficile infection, International Journal of Antimicrobial Agents, 2025, 65(5) (3) Teng Xu; Fenfen Zhou; Li Wang; Shi Wu; Haihui Huang; Metronidazole-Resistant Clostridioides difficile: Genomic and Transcriptomic Traits Acquired under In vitro MetronidazoleInduction, Elsevier, 2022, 59(5) (4) Zhou F; Hamza T; Fleur AS; Zhang Y; Yu H; Chen K; Heath JE; Chen Y; Huang H; Feng H; Micewith Inflammatory Bowel Disease are Susceptible to Clostridium difficile Infection With Severe Disease Outcomes, Inflamm Bowel Dis, 2018, 24(3): 573-582 (5）Zhao X#, Huang H#, Yuan H, Yuan Z, Zhang Y. A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections. J Antimicrob Chemother. 2022 May 29;77(6):1762-1769. (6)  Xu T, Wang L, Li J, Zhou F, Huang H*. Utility of a Simple Scoring System in Differentiating Bacterial Infections in Cases of Fever of Unknown Origin. Clin Infect Dis. 2020;71(S4):S409–15. (7) 吴湜,周芬芬,倪语星,胡云建,陈烨,俞云松,黄海辉.艰难梭菌核酸检测试剂盒诊断艰难梭菌感染的多中心研究[J].中华检验医学杂志,2019,42(8):674-678. (8) 中华医学会器官移植学分会, 中华预防医学会医院感染控制学分会, 复旦大学华山医院抗生素研究所. 中国实体器官移植供者来源感染防控专家共识(2018版) [J] . 中华器官移植杂志, 2018, 39(1) : 41-52.( 执笔专家：蔡常洁，中山大学附属第一医院；范欣，北京协和医院；黄海辉，复旦大学附属华山医院；马玉燕，复旦大学附属中山医院；童荔，中山大学附属第一医院；王婷，复旦大学附属华山医院，张雷，海军军医大学长海医院)